dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Hammel, Pascal |
dc.contributor.author | Kindler, H. L. |
dc.contributor.author | Reni, M. |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Hall, Michael J |
dc.date.accessioned | 2021-04-20T11:30:52Z |
dc.date.available | 2021-04-20T11:30:52Z |
dc.date.issued | 2019-12 |
dc.identifier.citation | Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 Dec 1;30(12):1959–68. |
dc.identifier.issn | 1569-8041 |
dc.identifier.uri | https://hdl.handle.net/11351/5879 |
dc.description | Qualitat de vida relacionada amb la salut; Olaparib; Càncer de pàncrees |
dc.description.sponsorship | This study was sponsored by AstraZeneca and is part of an alliance between AstraZeneca and MSD (no grant number). This research was funded in part through the NIH/NCI Cancer Center Support Grant P30-17 CA008748. |
dc.language.iso | eng |
dc.publisher | Oxford University Press |
dc.relation.ispartofseries | Annals of Oncology;30 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer |
dc.subject | Metàstasi |
dc.subject | Medicaments antineoplàstics |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neoplasm Metastasis |
dc.subject.mesh | Quality of Life |
dc.title | Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1093/annonc/mdz406 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | metástasis neoplásica |
dc.subject.decs | calidad de vida |
dc.relation.publishversion | https://www.sciencedirect.com/science/article/pii/S092375342032559X?via%3Dihub |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Hammel P] Department of Digestive Oncology, Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France. [Kindler HL] Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA. [Reni M] Department of Oncology, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy. [Van Cutsem E] Division of Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology, Barcelona, Spain. [Hall MJ] Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA |
dc.identifier.pmid | 31562758 |
dc.identifier.wos | 000507595800013 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |